|
|
| (One intermediate revision not shown.) |
| Line 3: |
Line 3: |
| | <StructureSection load='6uux' size='340' side='right'caption='[[6uux]], [[Resolution|resolution]] 1.50Å' scene=''> | | <StructureSection load='6uux' size='340' side='right'caption='[[6uux]], [[Resolution|resolution]] 1.50Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6uux]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Blood_fluke Blood fluke]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6UUX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6UUX FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6uux]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Schistosoma_mansoni Schistosoma mansoni]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6UUX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6UUX FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=A3P:ADENOSINE-3-5-DIPHOSPHATE'>A3P</scene>, <scene name='pdbligand=QHM:hycanthone'>QHM</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.5Å</td></tr> |
| - | <tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=CAS:S-(DIMETHYLARSENIC)CYSTEINE'>CAS</scene></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A3P:ADENOSINE-3-5-DIPHOSPHATE'>A3P</scene>, <scene name='pdbligand=CAS:S-(DIMETHYLARSENIC)CYSTEINE'>CAS</scene>, <scene name='pdbligand=QHM:1-{[2-(diethylamino)ethyl]amino}-4-(hydroxymethyl)-9H-thioxanthen-9-one'>QHM</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">SULT-OR, Smp_089320 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=6183 Blood fluke])</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6uux FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6uux OCA], [https://pdbe.org/6uux PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6uux RCSB], [https://www.ebi.ac.uk/pdbsum/6uux PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6uux ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6uux FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6uux OCA], [http://pdbe.org/6uux PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6uux RCSB], [http://www.ebi.ac.uk/pdbsum/6uux PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6uux ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | + | == Function == |
| | + | [https://www.uniprot.org/uniprot/G4VLE5_SCHMA G4VLE5_SCHMA] |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 18: |
Line 19: |
| | </div> | | </div> |
| | <div class="pdbe-citations 6uux" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 6uux" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Sulfotransferase 3D structures|Sulfotransferase 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Blood fluke]] | |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| - | [[Category: Taylor, A B]] | + | [[Category: Schistosoma mansoni]] |
| - | [[Category: Drug resistance]] | + | [[Category: Taylor AB]] |
| - | [[Category: Hycanthone]]
| + | |
| - | [[Category: Parasite]]
| + | |
| - | [[Category: Schistosome]]
| + | |
| - | [[Category: Sulfotransferase]]
| + | |
| - | [[Category: Transferase]]
| + | |
| Structural highlights
Function
G4VLE5_SCHMA
Publication Abstract from PubMed
Hycanthone (HYC) is a retired drug formerly used to treat schistosomiasis caused by infection from Schistosoma mansoni and S. haematobium. Resistance to HYC was first observed in S. mansoni laboratory strains and in patients in the 1970s and the use of this drug was subsequently discontinued with the substitution of praziquantel (PZQ) as the single antischistosomal drug in the worldwide formulary. In endemic regions, multiple organizations have partnered with the World Health Organization to deliver PZQ for morbidity control and prevention. While the monotherapy reduces the disease burden, additional drugs are needed to use in combination with PZQ to stay ahead of potential drug resistance. HYC will not be reintroduced into the schistosomiasis drug formulary as a combination drug because it was shown to have adverse properties including mutagenic, teratogenic and carcinogenic activities. Oxamniquine (OXA) was used to treat S. mansoni infection in Brazil during the brief period of HYC use, until the 1990s. Its antischistosomal efficacy has been shown to work through the same mechanism as HYC and it does not possess the undesirable properties linked to HYC. OXA demonstrates cross-resistance in Schistosoma strains with HYC resistance and both are prodrugs requiring metabolic activation in the worm to toxic sulfated forms. The target activating enzyme has been identified as a sulfotransferase enzyme and is currently used as the basis for a structure-guided drug design program. Here, we characterize the sulfotransferases from S. mansoni and S. haematobium in complexes with HYC to compare and contrast with OXA-bound sulfotransferase crystal structures. Although HYC is discontinued for antischistosomal treatment, it can serve as a resource for design of derivative compounds without contraindication.
Molecular basis for hycanthone drug action in schistosome parasites.,Guzman M, Rugel A, Tarpley RS, Cao X, McHardy SF, LoVerde PT, Taylor AB Mol Biochem Parasitol. 2020 Feb 3;236:111257. doi:, 10.1016/j.molbiopara.2020.111257. PMID:32027942[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Guzman M, Rugel A, Tarpley RS, Cao X, McHardy SF, LoVerde PT, Taylor AB. Molecular basis for hycanthone drug action in schistosome parasites. Mol Biochem Parasitol. 2020 Feb 3;236:111257. doi:, 10.1016/j.molbiopara.2020.111257. PMID:32027942 doi:http://dx.doi.org/10.1016/j.molbiopara.2020.111257
|
